T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
SAN FRANCISCO and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial. The IMAG1NE trial is designed to evaluate the safety and preliminary efficacy of TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) specific for the Melanoma-associated Antigen Gene-A1 (MAGE-A1), in patients with solid tumors.
SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing...
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing.Â
The series B round positions T-knife to start assessing whether its mouse platform can bring the benefits of cell therapies to solid tumors.